newsfilter
← Earnings
Earnings Releases·

Iambic Therapeutics — Third Quarter 2026 Earnings Summary

  • Collaboration revenue surged to $11.4 million in Q3 2026 from $4.7 million in Q3 2025, with year-to-date billings reaching approximately $100 million versus $19.0 million in the prior year period.
  • Net loss widened to $38.5 million for Q3 2026 from $21.5 million in Q3 2025, driven by increased R&D and G&A expenses, though the loss included a $10.4 million non-cash charge related to convertible notes.
  • The company closed its IPO in October 2026, generating $156 million in net proceeds, bringing pro-forma cash and cash equivalents to approximately $455 million as of September 30, 2026.
  • Strategic progress includes the launch of the Enchant v3 AI model, positive Phase 1/2 data for IAM1363 showing 36% systemic response rates, and IND approvals for IAM217 with an IAM-C1 submission expected in Q4 2026.
  • Total partnerships have expanded to eight since 2024, including new collaborations with Bayer and AbbVie, while deferred revenue increased significantly to $96.1 million from $20.4 million at the end of 2025.
Company
IAMBIC THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology